← Stock Trading Canary · All insider profiles
INSIDER PROFILE · ES
SOLEDAD CUENCA MIRANDA
Persona con Responsabilidad de Dirección
Profile key: es|soledad cuenca miranda
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 4
- Purchases · 24M
- 6
- Average purchase
- €12,209
- Gross purchase value
- €73,256
- Last purchase
- 2026-06-16
- Completed 20D events
- 6.0
- Outcome status
- PASS
Latest company: PHARMA MAR, S.A.
Companies: PHARMA MAR, S.A.
Post-purchase outcomes
Benchmark-relative outcomes are available against IBEX 35.
- Excess return = stock return − IBEX 35 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 6Developing | 100.0% (6/6) | 66.7% (4/6) | +2.6% | +1.6% | -6.2% |
| 20D | 6Developing | 100.0% (6/6) | 66.7% (4/6) | +3.7% | -1.8% | -21.4% |
| 60D | 6Developing | 100.0% (6/6) | 16.7% (1/6) | -15.3% | -13.7% | -34.2% |
| 120D | 5Developing | 100.0% (5/5) | 20.0% (1/5) | -15.8% | -9.0% | -28.0% |
Research patterns
- First purchase in 12M
- 1/6
- Large purchase ≥ €100k
- 0/6
- Cluster buying · 15D
- 2/6
- Buying the dip · ≥20% below prior 52W high
- 2/6
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.